---
document_datetime: 2026-02-11 11:22:28
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/qinlock-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: qinlock-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 11.7705972
conversion_datetime: 2026-02-13 18:44:25.774726
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.2
  docling: 2.73.1
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## QINLOCK

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber      | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued²/ amendedon   | Product Information affected3   | Summary   |
|------------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA_IN / | This was an application for a group of | 11/02/2026                          |                                          | SmPC,Annex                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000326560   | variations.   | II, Labelling and PL   |
|---------------------|---------------|------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | batch release of the finished product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000296456 | B.IACTIVESUBSTANCE-B.I.zOther variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 07/10/2025 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Variation type IB / EMA/VR/0000296131 | B.II.FINISHED PRODUCT-B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 02/10/2025 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Variation type II / EMA/VR/0000284381 | Thiswas an applicationfor agroupof variations. C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.4 Change(s) in the Summary of Product Characteristics, LabellingorPackageLeafletduetonew quality, preclinical, clinical or pharmacovigilance data- Accepted C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.4 Change(s) in the Summary of Product Characteristics, LabellingorPackageLeafletduetonew quality, preclinical, clinical or pharmacovigilance data - Accepted A grouped application consisting of:C.I.4: Updateofsection4.5of theSmPCbasedon results from drug-drug interaction study DCC-2618-01-007.Inaddition,the MAH took the opportunity to implement editorial | 11/09/2025 | SmPC and PL | SmPCnewtextSection4.5:Interactionwithother medicinal products and otherforms of interaction CYPisoform-selectivesubstratesRipretinibisa weakinhibitorofCYP2C8.Co-administration of QINLOCKwithrepaglinide(asensitiveindex substrateforCYP2C8)increasedrepaglinideAUcO- oby26%.RepaglinideCmaxwasunchanged; therefore, dose adjustment is not required. UGT1A substrates In vitro studies suggested that ripretinib is an inhibitor of UGT1A1, UGT1A3, UGT1A4, UGT1A7,andUGT1A8.QINLOCKistobeusedwith cautionin combinationwith clinicalsubstrates of UGT1A enzymes (e.g. bictegravir, cabotegravir, dolutegravir, raltegravir, lamotrigine), as co- administration may lead to increased exposure of these substrates. Clinical studies withUGT1A substrateshavenotbeenconducted.Section4.8: ThefrequencyofGrade3decreasedleftventricular ejection fraction in the pooled safety population was correctedto2%(previously4%).Formore information，pleaserefertotheSummaryofProduct |

<div style=\"page-break-after: always\"></div>

|                                       | changes to the PI, as well as,to update the list of representatives in the Packagae Leaflet.C.I.4:Update of section 4.5 of the SmPC based on results from in vitro study DCC-2618-03-0046toinvestigatethe interactionbetweenQINLOCKandUGT1A substrates.                                                                                                                                                                                                       |            | Characteristics.   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------|
| Variation type IB / EMA/VR/0000278855 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.z Other variation-Accepted C.I.z- to provide an updated Environmental RiskAssessmentreport.                                                                                                                                                                                                                                                                                                                       | 08/08/2025 |                    |
| Variation type IA / EMA/VR/0000286650 | This was an application for a group of variations. B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.11.b.4.a Up to10-foldcompared to the originally approvedbatch size-Accepted B.III.2.a Change of specification(s)of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a nationalpharmacopoeiaofaMemberState B.II1.2.a.2Excipient/active substance starting material - Accepted | 17/07/2025 |                    |
| Variation type IB / EMA/VR/0000271896 | B.I.a.4 Change to in-process tests orlimits applied during the manufacture of the active substance -B.I.a.4.cDeletion of a non- significantin-process test-Accepted                                                                                                                                                                                                                                                                                           | 23/05/2025 |                    |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000261098   | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediateusedinthemanufactureofthe finished product - B.II.b.3.z Other changes - Accepted   | 28/03/2025   |             |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------|
| PSUR/EMA/PSUR/0000288238                |                                                                                                                                                                                   |              | Maintenance |